Health Care·Biotechnology·$8.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | +23.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.85 | N/A | +23.42% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to long-term goals despite short-term setbacks.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its pipeline and operational efficiency.
Vaxcyte's earnings report showed a larger-than-expected loss per share, which was a positive surprise compared to expectations. However, the lack of revenue figures and guidance may have contributed to the stock's decline of 1.08%. Investors are likely concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AECOM
May 6, 2024